Astute investors do not believe that the company can fund phase 3 trials using 75 million dollars of Aspire dilution. The poster below does not believe it would be detrimental to current shareholders to have more than 100 million cheap shares hit the market. Not so astute IMO.
Partner up Leo before reality slaps some investors in the face.